466 related articles for article (PubMed ID: 21325402)
1. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.
Geisbert TW; Bailey M; Hensley L; Asiedu C; Geisbert J; Stanley D; Honko A; Johnson J; Mulangu S; Pau MG; Custers J; Vellinga J; Hendriks J; Jahrling P; Roederer M; Goudsmit J; Koup R; Sullivan NJ
J Virol; 2011 May; 85(9):4222-33. PubMed ID: 21325402
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
[TBL] [Abstract][Full Text] [Related]
3. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
4. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
5. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.
Stanley DA; Honko AN; Asiedu C; Trefry JC; Lau-Kilby AW; Johnson JC; Hensley L; Ammendola V; Abbate A; Grazioli F; Foulds KE; Cheng C; Wang L; Donaldson MM; Colloca S; Folgori A; Roederer M; Nabel GJ; Mascola J; Nicosia A; Cortese R; Koup RA; Sullivan NJ
Nat Med; 2014 Oct; 20(10):1126-9. PubMed ID: 25194571
[TBL] [Abstract][Full Text] [Related]
6. An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
Wu S; Kroeker A; Wong G; He S; Hou L; Audet J; Wei H; Zhang Z; Fernando L; Soule G; Tran K; Bi S; Zhu T; Yu X; Chen W; Qiu X
J Infect Dis; 2016 Oct; 214(suppl 3):S326-S332. PubMed ID: 27493239
[TBL] [Abstract][Full Text] [Related]
7. Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species.
Zahn R; Gillisen G; Roos A; Koning M; van der Helm E; Spek D; Weijtens M; Grazia Pau M; Radošević K; Weverling GJ; Custers J; Vellinga J; Schuitemaker H; Goudsmit J; Rodríguez A
PLoS One; 2012; 7(12):e44115. PubMed ID: 23236343
[TBL] [Abstract][Full Text] [Related]
8. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
[TBL] [Abstract][Full Text] [Related]
9. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
10. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection.
Marzi A; Murphy AA; Feldmann F; Parkins CJ; Haddock E; Hanley PW; Emery MJ; Engelmann F; Messaoudi I; Feldmann H; Jarvis MA
Sci Rep; 2016 Feb; 6():21674. PubMed ID: 26876974
[TBL] [Abstract][Full Text] [Related]
12. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
[TBL] [Abstract][Full Text] [Related]
13. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
[TBL] [Abstract][Full Text] [Related]
14. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2017 May; 91(10):. PubMed ID: 28250127
[TBL] [Abstract][Full Text] [Related]
15. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
17. Open-label phase I clinical trial of Ad5-EBOV in Africans in China.
Wu L; Zhang Z; Gao H; Li Y; Hou L; Yao H; Wu S; Liu J; Wang L; Zhai Y; Ou H; Lin M; Wu X; Liu J; Lang G; Xin Q; Wu G; Luo L; Liu P; Shentu J; Wu N; Sheng J; Qiu Y; Chen W; Li L
Hum Vaccin Immunother; 2017 Sep; 13(9):2078-2085. PubMed ID: 28708962
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice.
Wang L; Liu J; Kong Y; Hou L; Li Y
Hum Gene Ther; 2018 Jan; 29(1):87-95. PubMed ID: 28795602
[TBL] [Abstract][Full Text] [Related]
19. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
20. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.
Herbert AS; Kuehne AI; Barth JF; Ortiz RA; Nichols DK; Zak SE; Stonier SW; Muhammad MA; Bakken RR; Prugar LI; Olinger GG; Groebner JL; Lee JS; Pratt WD; Custer M; Kamrud KI; Smith JF; Hart MK; Dye JM
J Virol; 2013 May; 87(9):4952-64. PubMed ID: 23408633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
